A Phase 4 interventional study of Ketamine and Normal saline in Chronic Pain and Depression, sponsored by Stanford University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-10-02.
Sponsored by Stanford University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing ketamine in Chronic Pain — 4 open to participants now, 5 under way, 1 of them phase 3. Ketamine · Chronic Pain.
Among the 32 studies testing ketamine in Chronic Pain, this one is the 17th largest by planned enrollment, is the only one that started in 2025, is one of 8 in phase 4, and was the 29th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →4 of the 32 studies testing ketamine in Chronic Pain are open now, in 2 countries. Recruiting first, the newest first:
Dr. Yuliya Knyahnytska · Sites in Canada
Ages 18–64
University Health Network, Toronto · Sites in Canada
Ages 18–75
University of Rochester · Sites in United States
Ages 18+
Aga Khan University
Ages 18–75 · Women only
By country, each count listing its studies:
Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 7 · Phase 4 8
First in 2007; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 44 across the 32 interventional studies. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 32 have an industry lead sponsor. The 10 most frequent:
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
47 studies in Chronic Pain by Stanford University: 14 open now, 18 under way, 1 of them phase 3. Of 22 finished, 10 (45%) have results posted.
Among the 47 studies in Chronic Pain by Stanford University, this one is the 26th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2025, is one of 3 in phase 4, reaches primary completion later than 3 of the 17 other live ones, and was the 39th registered.
Stanford University’s Chronic Pain studies by the year they started, since 1998.
3 of the studies testing ketamine in Chronic Pain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05306899Phase 3University Health Network, TorontoMulti-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches | 2027-02-01 |
| NCT06317636Stanford UniversityPropofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression | 2026-11 |
| NCT07197684Aga Khan UniversityUltrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surgery | 2026-12-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing ketamine in Chronic Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Stanford University’s 47 in Chronic Pain:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare ketamine to a placebo when given as a single infusion during IV sedation in adults with chronic pain and depression. We do not know whether ketamine will be more effective than placebo under these circumstances.
This study aims to:
Participants will:
Ketamine is a dissociative anesthetic that has been in clinical use for more than 50 years. In addition to its well-known anesthetic and pain-relieving properties, ketamine has been found to have fast-acting antidepressant effects in patients with depression. However, the mechanisms underlying ketamine's ability to treat chronic pain and depression are poorly understood. A most basic question regarding ketamine's therapeutic mechanism is still unresolved: do patients need to consciously experience and recall ketamine's acute dissociative effects to receive lasting analgesic and antidepressant benefits? In this clinical trial, participants will receive either ketamine or a placebo when they are under sedation with propofol. A n=6 pilot feasibility phase will precede the fully-powered n=34 randomized controlled trial.
Enrollment for the n=6 pilot phase is complete as of 6/19/2025.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A one-time intravenous infusion of ketamine (0.5 mg/kg)
Drug: Ketamine
A one-time intravenous infusion of normal saline
Drug: Normal saline
0.5 mg/kg ketamine infused intravenously over 40 minutes
Also known as: Ketalar
0.9% normal saline infused intravenously over 40 minutes
Also known as: 0.9% NaCl
Pain intensity in the past 24 hours
A numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain) over the past 24 hours will be used to assess pain intensity.
Time frame: screening; 1, 7, 14, 21 and 28 days after treatment
Depression Severity and Blinding
The 16-item Quick Inventory of Depressive Symptomatology Self-Report will be used to assess the severity of depressive symptoms. Items are self-rated on a 4-point scale tailored to each depression-related symptom. Higher total scores indicate greater depression symptom severity. Blinding will be assessed by asking participants to guess which treatment they received and rate their certainty on a simple 0-100 scale.
Time frame: screening; day of infusion pre-treatment; 7, 14, 21 and 28 days after treatment
Number and severity of adverse events related to sedation
Adverse events (AEs) will be assessed through a combination of patient self-report, interviews by study staff, and surveillance of medical records by the research team. AEs will be graded by severity (1=mild, 2=moderate, 3=severe, 4=life threatening, and 5=death) and relatedness to the intervention (0=definitely unrelated, 1=unlikely, 2=possibly related, 3=probably related, 4 definitely related).
Time frame: during treatment; day of infusion post-treatment; 1, 7, 14, 21 and 28 days after treatment
Side effects related to ketamine
The Ketamine Side Effect Tool (KSET) is a standardized questionnaire designed to systematically assess the side effects experienced during or after ketamine administration. It covers a range of potential adverse effects, including dissociative, cardiovascular, and psychotomimetic symptoms. Participants are asked to rate the severity of each adverse effect as 'Never', 'Mild', 'Moderate', or 'Severe'.
Time frame: day of infusion post-treatment; 1, 7, 14, 21 and 28 days after treatment
Proportion of participants who accurately recall intra-sedation events
Participants will be interviewed by study staff using the modified Brice Questionnaire, a set of questions asked in sequence to determine if the participant remembers anything between the time of induction and their awakening.
Time frame: day of infusion post-treatment
Participant expectations
Expectations will be measured by asking participants to rate how effective they expect their treatment will be using a visual analog sliding scale from 0 ("Not effective at all") to 100 ("Completely effective"). They will then be asked to rate their level of confidence on a scale from 0 to 100%.
Time frame: screening; day of infusion post-treatment; 1, 7, 14, 21 and 28 days after treatment
Pressure pain threshold
A pressure algometer device applied to the upper trapezius muscle will measure the pressure pain threshold by applying a controlled, gradually increasing force until the participant reports pain.
Time frame: day of infusion pre-treatment; day of infusion post-treatment
Mechanical temporal summation
Mechanical temporal summation will be measured by applying the blunt tip of a thin flexible filament to the back of the hand and the lumbar region. Participants will be asked report pain intensity on a sale from 0 to 100 after a single application and after 10 repeated applications.
Time frame: day of infusion pre-treatment; day of infusion post-treatment
Conditioned pain modulation
Conditioned pain modulation (CPM) measures the ability of the nervous system to inhibit a painful stimulus in the presence of another aversive stimulus. In this study, participants will immerse one hand in cold water and undergo pressure pain threshold measurements in the opposite trapezius muscle before, during, and after immersion.
Time frame: day of infusion pre-treatment; day of infusion post-treatment
Number of painful body regions
The CHOIR Body Map is a visual tool that allows individuals to indicate the location(s) of their pain on a human body outline.
Time frame: screening; day of infusion pre-treatment; day of infusion post-treatment; 1, 7, 14, 21 and 28 days after treatment
Pain interference
The 8-item PROMIS Pain Interference Short Form assesses the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. Items are self-rated on a 5-point scale ranging from 1 ("Not at all") to 5 ("Very Much"). Raw score totals are converted to standardized T-scores, with a higher T-score representing greater pain interference.
Time frame: screening; day of infusion pre-treatment; 7, 14, 21 and 28 days after treatment
Change in pain medication utilization
Participants are asked to rate how their pain medication usage has changed compared to before treatment
Time frame: 1, 7, 14, 21 and 28 days after treatment
Physical function
The 20-item PROMIS Physical Function Short Form assesses the ability to carry out physical tasks and activities in one's daily life. Items are self-rated on a 5-point scale ranging from 1 ("Unable to do") to 5 ("Without any difficulty"). Raw score totals are converted to standardized T-scores, with a higher T-score representing better physical function.
Time frame: screening; day of infusion pre-treatment; 7, 14, 21 and 28 days after treatment
Sleep disturbance
The 8-item PROMIS Sleep Disturbance Short Form assesses an individual's perception of their sleep quality. Items are self-rated on a 5-point scale ranging from 1 ("Not at all") to 5 ("Very much"). Raw scores are converted to standardized T-scores, with higher a T-score representing more severe sleep disturbance.
Time frame: screening; day of infusion pre-treatment; 7, 14, 21 and 28 days after treatment
Anxiety symptom severity
The 7-item Generalized Anxiety Disorder (GAD-7) Scale assesses the severity of anxiety symptomsover the past two weeks. Items are self-rated on a 4-point scale ranging from 0 ("Not at all") to 3 ("Nearly every day"), reflecting the frequency of symptoms. Higher total scores indicate greater anxiety symptom severity.
Time frame: screening; day of infusion pre-treatment; 14 and 28 days after treatment]
Peace of mind
The 7-item Peace of Mind Scale assesses an individual's overall sense of inner calm and contentment. Items are self-rated on a 5-point scale ranging from 1 ("Not at all") to 5 ("All of the time"). Higher total scores reflect a greater sense of peace of mind.
Time frame: screening; day of infusion pre-treatment; 7 and 28 days after treatment
Emotion regulation
The 10-item Emotion Regulation Questionnaire assesses individual differences in the habitual use of cognitive reappraisal and expressive suppression strategies. Items are self-rated on a 7-point scale ranging from 1 ("Strongly disagree") to 7 ("Strongly agree"). Higher scores on the cognitive reappraisal subscale indicate a greater tendency to reinterpret situations to manage emotions, while higher scores on the expressive suppression subscale indicate a greater tendency to inhibit outward emotional expression.
Time frame: screening; day of infusion pre-treatment; 7 and 28 days after treatment
Anhedonia
The 14-item Snaith-Hamilton Pleasure Scale measures an individual's capacity to experience pleasure from various activities over the past 2 weeks, the absence of which indicates anhedonia. Items are self-rated on a 4-point scale ranging from 0 ("Strongly disagree") to 3 ("Strongly agree"). Lower total scores indicate greater degree of anhedonia.
Time frame: screening; day of infusion pre-treatment; 14 and 28 days after treatment
Enrollment rate
The total number of consented, eligible participants enrolled by the end of the study divided by the amount of time between date of opening enrollment and the date of consent from the last participant.
Time frame: from date of opening enrollment to the date of consent from the last participant, assessed up to 60 months
Consent fraction
The proportion of patients who are contacted by study staff for recruitment who provide written informed consent to study procedures.
Time frame: from date of opening enrollment to the date of consent from the last participant, assessed up to 60 months
Participant Experience Survey
Participants are asked at the end of the study to rate their experience with study procedures and to provide feedback for improvement.
Time frame: through study completion, an average of 4 weeks
Plan to share: Yes — De-identified participant data, study outcomes, and data dictionaries
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Available upon request after publication of the trial's primary findings for up to 5 years.
Access criteria: Researchers must submit a brief proposal and statistical analysis plan for review and approval by the investigators and execute a data sharing agreement.
Started Jan 2025 (actual). Primary completion is estimated for Nov 2026, 22 months after the start.
Of 50 non-industry phase 4 interventional studies under Chronic Pain, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 22 months is close to that.
Counting every sponsor, half of 52 studies reached it within 24 months; a quarter within 14 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ketamine